Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 3 Months Ended
Jan. 31, 2019
Jan. 31, 2018
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (4,966,609) $ (1,865,474)
Stock option compensation to employees and directors 1,219,560 214,427
Stock options and warrants issued to consultants 46,219 52,546
Restricted stock award compensation to employee pursuant to stock incentive plan 1,484,385
Common stock issued to consultants 15,002
Depreciation of property and equipment 6,130 4,391
Amortization of patents 251,250 81,324
Impairment in carrying amount of patent assets 418,750
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee 64,656
Change in operating assets and liabilities:    
Prepaid expenses and other current assets 148,811 (103,930)
Accounts payable 30,928 (63,399)
Accrued expenses 31,040 260,464
Net cash used in operating activities (1,329,536) (1,339,993)
Cash flows from investing activities:    
Disbursements to acquire short-term investments in certificates of deposit (1,250,000)
Proceeds from maturities of short-term investments in certificates of deposit 250,000 2,100,000
Purchase of property and equipment (2,518)
Net cash provided by investing activities 250,000 847,482
Cash flows from financing activities:    
Net proceeds from sale of common stock in at-the-market offering 2,153,584
Proceeds from exercise of employee stock options 22,700
Net cash provided by financing activities 2,176,284
Net increase (decrease) in cash and cash equivalents 1,096,748 (492,511)
Cash and cash equivalents at beginning of period 3,055,890 3,339,374
Cash and cash equivalents at end of period $ 4,152,638 $ 2,846,863